FDA Announces Draft Guidance for Industry on Product-Specific Guidance Meetings Under GDUFA

Summary

The FDA has released a draft guidance outlining procedures for product-specific guidance meetings between the agency and abbreviated new drug applicants under the Generic Drug User Fee Act, aiming to promote well-managed meetings and ensure compliance with the GDUFA III commitment letter.